Coherus BioSciences, Inc. (CHRS) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 10, 2024, announces that Coherus BioSciences, Inc. will present preliminary unaudited revenue results for the fiscal year ended December 31, 2023, at the 42nd Annual J.P. Morgan Healthcare Conference. The filing serves as a notification of these upcoming disclosures rather than a final financial report.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The actual financial figures are contained in Exhibit 99.1 (presentation slides) and the company's investor relations website, which are referenced but not included in the body of this 8-K text.
Material Changes and Comparisons
No material changes versus prior periods are detailed in this document. The filing explicitly states that the financial closing procedures for the quarter and fiscal year ended December 31, 2023, are not yet complete. Consequently, final results may vary materially from the preliminary unaudited results to be presented.
Guidance, Outlook, and Risks
- Unaudited Status: The preliminary financial information is based on currently available data and has not been reviewed or audited by the company's independent registered public accounting firm.
- Cautionary Note: Management warns that final closing procedures could result in significant changes to the preliminary results.
- Legal Disclaimer: The information furnished in this Item 2.02 and Exhibit 99.1 is not deemed "filed" under the Exchange Act and is not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Investor Verification Checklist
- Verify the final audited financial statements once the company completes its closing procedures.
- Review Exhibit 99.1 (the presentation slides) on the company's investor relations website for the specific preliminary revenue figures.
- Confirm whether the preliminary results presented at the J.P. Morgan Healthcare Conference align with the final audited numbers released in the subsequent 10-K filing.
- Monitor for any material adjustments to the preliminary data due to the incomplete closing procedures noted in the filing.